Panobinostat: all 136 studies that test it

Page 1 of 2. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Optimizing Reversal of HIV Latency With Combination TherapyNot yet recruitingNCT06240520Phase 1/2
• Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
• Study of Panobinostat (LBH589) in Patients With Sickle Cell DiseaseRecruitingNCT01245179Phase 1
• Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)TerminatedNCT04804709Phase 1Results posted
• Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT03256045Phase 2Results posted
• Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)CompletedNCT02722941Phase 2Results posted
• A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)TerminatedNCT02720510Phase 2Results posted
• Trial of Panobinostat in Children With Diffuse Intrinsic Pontine GliomaCompletedNCT02717455Phase 1Results posted
• Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple MyelomaCompletedNCT02654990Phase 2Results posted
• Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) PreventionCompletedNCT02588339Phase 2Results posted
• Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or LymphomaTerminatedNCT02518750Phase 2Results posted
• Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple MyelomaCompletedNCT02506959Phase 2Results posted
• Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral TherapyCompletedNCT02471430Phase 1/2Results posted
• Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT02290431Phase 2Results posted
• MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple MyelomaCompletedNCT02057640Phase 1/2Results posted
• Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV MelanomaCompletedNCT02032810Phase 1Results posted
• Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the InvestigatorCompletedNCT01802879Phase 2Results posted
• Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)CompletedNCT01693601Phase 1/2Results posted
• Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)CompletedNCT01651039Phase 2Results posted
• Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib TosylateTerminatedNCT01582009Phase 1/2Results posted
• Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCTCompletedNCT01523834Phase 2Results posted
• Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01496118Phase 1/2Results posted
• A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT01460940Phase 2Results posted
• Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaTerminatedNCT01282476Phase 2Results posted
• Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01261247Phase 2Results posted
• Re-expression of ER in Triple Negative Breast CancersTerminatedNCT01194908Phase 1/2Results posted
• Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin LymphomaCompletedNCT01169636Phase 1/2Results posted
• Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)CompletedNCT01111526Phase 1/2Results posted
• Panobinostat and Letrozole in Treating Patients With Metastatic Breast CancerCompletedNCT01105312Phase 1/2Results posted
• Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)TerminatedNCT01090973Phase 2Results posted
• Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple MyelomaCompletedNCT01083602Phase 2Results posted
• Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine TherapyTerminatedNCT01056601Phase 2Results posted
• A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)CompletedNCT01034163Phase 3Results posted
• Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple MyelomaCompletedNCT01023308Phase 3Results posted
• Trial of LBH589 in Metastatic Thyroid CancerCompletedNCT01013597Phase 2Results posted
• Study of Panobinostat in Patients With Neuroendocrine TumorsTerminatedNCT00985946Phase 2Results posted
• Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT00978432Phase 2Results posted
• Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory LymphomaCompletedNCT00967044Phase 1/2Results posted
• A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).CompletedNCT00946647Phase 1/2Results posted
• Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)TerminatedNCT00939159Phase 2Results posted
• LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's MacroglobulinemiaCompletedNCT00936611Phase 2Results posted
• A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary MyelofibrosisTerminatedNCT00931762Phase 2Results posted
• Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and PanobinostatTerminatedNCT00925132Phase 1/2Results posted
• Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaCompletedNCT00918333Phase 1/2Results posted
• Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)CompletedNCT00880269Phase 2Results posted
• Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After CastrationCompletedNCT00878436Phase 1/2Results posted
• LBH589 and Bevacizumab in Patients With Recurrent High Grade GliomaCompletedNCT00859222Phase 1/2Results posted
• Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast CancerCompletedNCT00777049Phase 2Results posted
• Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple MyelomaCompletedNCT00743288Phase 1/2Results posted
• Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's LymphomaCompletedNCT00742027Phase 2Results posted
• Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaTerminatedNCT00723203Phase 2Results posted
• LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)CompletedNCT00691938Phase 1/2Results posted
• Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate CancerCompletedNCT00667862Phase 2Results posted
• A Study of Oral LBH589 in Adult Patients With Advanced Hematological MalignanciesCompletedNCT00621244Phase 1/2Results posted
• LBH589 in Refractory Myelodysplastic Syndromes (MDS)TerminatedNCT00594230Phase 2Results posted
• A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After TrastuzumabTerminatedNCT00567879Phase 1/2Results posted
• LBH589 Treatment for Refractory Clear Cell Renal CarcinomaCompletedNCT00550277Phase 2Results posted
• Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)TerminatedNCT00490776Phase 2Results posted
• Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic PhaseTerminatedNCT00451035Phase 2Results posted
• Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast PhaseTerminatedNCT00449761Phase 2Results posted
• Efficacy and Safety of LBH589B in Adult Patients With Multiple MyelomaTerminatedNCT00445068Phase 2Results posted
• Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell LymphomaCompletedNCT00425555Phase 2Results posted
• A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRTTerminatedNCT04897880Phase 2
• Phase I Study of Marizomib + Panobinostat for Children With DIPGTerminatedNCT04341311Phase 1
• Panobinostat Maintenance After HSCT fo High-risk AML and MDSTerminatedNCT04326764Phase 3
• PDR001 + Panobinostat for Melanoma and NSCLCWithdrawnNCT03982134Phase 1
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With GliomasWithdrawnNCT03632317Phase 2
• Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed LymphomaWithdrawnNCT02961816Phase 2
• A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedNCT02890069Phase 1
• Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,PanobinostatWithdrawnNCT02802163Phase 1/2
• Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple MyelomaWithdrawnNCT02756663Phase 2
• Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT02676323Phase 1
• CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4
• Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple MyelomaStatus unknownNCT02145715Phase 1/2
• A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple MyelomaCompletedNCT01965353Phase 1
• Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's LymphomaStatus unknownNCT01884428Phase 1
• Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAARTCompletedNCT01680094Phase 1/2
• Panobinostat Biological Correlates StudyCompletedNCT01658241Phase 2
• A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) PatientsCompletedNCT01613976Phase 1
• Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple MyelomaCompletedNCT01549431Phase 1
• Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)TerminatedNCT01528501Phase 2
• Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT01504776Phase 1
• Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic SyndromeCompletedNCT01463046Phase 1
• Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)Status unknownNCT01451268Phase 1/2
• Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) PatientsCompletedNCT01440582Phase 1
• Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosisCompletedNCT01433445Phase 1
• Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven TumorsStatus unknownNCT01341834Phase 1
• Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid TumorsCompletedNCT01336842Phase 1
• Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT01301807Phase 1
• LBH589 (Panobinostat) for the Treatment of MyelofibrosisStatus unknownNCT01298934Phase 1/2
• Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)CompletedNCT01242774Phase 1
• Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based ChemotherapyTerminatedNCT01238965Phase 1
• LBH Phase II in Small Cell Lung Cancer (SCLC)CompletedNCT01222936Phase 2
• Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent ChordomaStatus unknownNCT01175109Phase 1
• Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung CancerWithdrawnNCT01160731Phase 1
• LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid TumorsStatus unknownNCT01159418Phase 1
• Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment FailureCompletedNCT01136499Phase 2
• A Panobinostat PresurgeryWithdrawnNCT01115036Phase 2
• Panobinostat (LBH589) in Patients With Metastatic MelanomaCompletedNCT01065467Phase 1

← Panobinostat overview